CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

This study tests CAR-T cell therapy — a treatment where a patient's own immune cells are engineered in a lab to target cancer — for people with relapsed or refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL) that has not responded to other treatments. **You may be eligible if...** - You are 18–80 years old with B-cell ALL or B-cell NHL that has relapsed or not responded to treatment - Your cancer cells express a marker called CD19 - You have relapsed after a stem cell transplant, are ineligible for transplant, or have had multiple relapses - Women of childbearing age must have a negative pregnancy test **You may NOT be eligible if...** - You have an active serious infection - You are known to have certain autoimmune conditions or prior organ transplants that would make this treatment unsafe - You are pregnant or breastfeeding - You have significant heart, lung, liver, or kidney problems Talk to your doctor to see if this trial is right for you.